Genfit Launches NASHnext with Labcorp for Non-Invasive MASH Diagnosis
Genfit announced on Monday the launch of NASHnext, a non-invasive diagnostic service based on its NIS4 technology, through Labcorp's OnDemand platform. This market deployment expands access to its tool for identifying patients with MASH (metabolic fatty liver disease).
A Diagnostic Service Marketed Through a Large Laboratory Network
NASHnext, powered by Genfit's NIS4 technology, is now available to patients through Labcorp's OnDemand offering. This service aims to identify at-risk patients suffering from MASH. The partnership with Labcorp marks the expansion of diagnostic distribution beyond traditional channels, leveraging the extensive network of analysis laboratories.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning
✓ Euronext data
✓ AI-powered analysis
Indicative data. No investment advice. Unsubscribe at any time.
Related
🏢
Other stocks — Santé
🗞️
Nanobiotix Stock Rebounds Nearly 2%, But Remains Below Its 50-Day Moving Average
🗞️
DBV Technologies Stock Breaks Key Support and Slides Over 2%
🗞️
Philips: AI Saves Clinicians 132 Hours Annually, According to Its 2026 Index
🗞️
Lakefront Biotherapeutics Appoints Eric Hedrick as Medical Director
